Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of BMS-986165 added to background therapy in lupus nephritis
MOH_2019-09-11_007166Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deucravacitinib in lupus nephritis (LN) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Efficacy of BMS-986165 in lupus nephritis and Safety of BMS-986165. Started Aug 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on MOH_2019-09-11_007166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-11_007166.